Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study

Maraviroc Reduces the Regulatory T-Cell Frequency in Antiretroviral-Naive HIV-Infected Subjects

(2014) María Mar Pozo-Balado et al.   JOURNAL OF INFECTIOUS DISEASES

Association of Higher Plasma Vitamin D Binding Protein and Lower Free Calcitriol Levels with Tenofovir Disoproxil Fumarate Use and Plasma and Intracellular Tenofovir Pharmacokinetics: Cause of a Functional Vitamin D Deficiency?

(2013) Peter L. Havens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study

(2013) Graeme J Moyle et al.   ANTIVIRAL THERAPY

Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation

(2013) P. M. Grant et al.   CLINICAL INFECTIOUS DISEASES

Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial

(2013) Stefano Rusconi et al.   PLoS One

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

(2012) Roger Bedimo et al.   AIDS

In vitro effects of the CCR5 inhibitor maraviroc on human T cell function

(2012) H. Arberas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4+ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256

(2012) T. J. Wilkin et al.   JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials

(2011) Thomas N. Kakuda et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg

(2011) C. Okoli et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

(2011) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

(2010) Hans‐Jürgen Stellbrink et al.   CLINICAL INFECTIOUS DISEASES

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial*

(2010) AB Hansen et al.   HIV MEDICINE

Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection

(2010) Philip M. Grant et al.   PLoS One

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients

(2010) Nicholas Funderburg et al.   PLoS One

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir

(2009) Marit GA van Vonderen et al.   AIDS

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

(2009) Claudine Duvivier et al.   AIDS

Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen

(2009) Todd T Brown et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Circulating Levels of Inflammatory Markers Predict Change in Bone Mineral Density and Resorption in Older Adults: A Longitudinal Study

(2008) Changhai Ding et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

(2008) Roy M. Gulick et al.   NEW ENGLAND JOURNAL OF MEDICINE